Journal Article

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

Marian Iwamoto, Larissa A. Wenning, Goutam C. Mistry, Amelia S. Petry, Sarah Y. Liou, Kaylan Ghosh, Sheila Breidinger, Neal Azrolan, Maria J. Gutierrez, William E. Bridson, Julie A. Stone, Keith M. Gottesdiener and John A. Wagner

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 47, issue 1, pages 137-140
Published in print July 2008 | ISSN: 1058-4838
Published online July 2008 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/588794
Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir.

Journal Article.  2294 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.